1. Short title
This Act may be cited as the Greater Access to Contraceptive Options Act.2. Applications for non-prescription contraceptive methods
(a) Priority review of application
The Secretary of Health and Human Services (referred to in this section as the Secretary) shall give priority review to any supplemental application submitted under section 505(b), 510(k), or 515 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(b), 360, 360e) for a self-administered contraceptive method to be marketed without being subject to section 503(b)(1) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 353(b)(1)) or treated as a prescription device.(b) Fee waiver
The Secretary shall waive the fee under section 736(a)(1) or 738(a)(2) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 379h(a)(1); 379j(a)(2)) (as applicable) with respect to a supplemental application that receives priority review under subsection (a).(c) Applicability
This section applies with respect to a supplemental application described in subsection (a) thatâ€”
(1) is submitted before the date of enactment of this Act and remains pending as of such date of enactment; or
(2) is submitted after such date of enactment.(d) Self-Administered contraceptive method defined
In this Act, the term self-administered contraceptive method means a drug or device (as those terms are defined in section 201 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 321)) or combination product approved for use under the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 321 et seq.) as a method of contraception that is administered without the intervention of a health care professional, including the birth control pill, patch, vaginal ring, or injection, such as depot medroxyprogesterone acetate.